# NIH grant: Personalized Diabetes Management through iPSC-Derived β-cells: A Tailored Approach for Improving Treatment Efficacy in Economically Vulnerable Populations (1R43DK142739-01A1) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/a47111aed0c357cb

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-08-15 00:00 ingested 2026-08-17 06:47

[original source ↗](https://reporter.nih.gov/project-details/1R43DK142739-01A1)

## retained text



```
NIH grant 1R43DK142739-01A1: Personalized Diabetes Management through iPSC-Derived β-cells: A Tailored Approach for Improving Treatment Efficacy in Economically Vulnerable Populations
Institute: {'code': 'DK', 'abbreviation': 'NIDDK', 'name': 'National Institute of Diabetes and Digestive and Kidney Diseases', 'admin_org_id': '12500020', 'admin_funding_url': ''}. PI: Noel  Moya. Award: $306863.
Start: 2026-08-15T00:00:00.
Delphi Stem LLC.
7. PROJECT SUMMARY
Diabetes mellitus (DM), a metabolic disorder caused by loss or dysfunction of insulin-producing
β-cells, affects over 537 million individuals globally, with projections reaching 783 million by 2045.
In 2021, 38.4 million Americans (11.6% of the population) were diagnosed with type 2 diabetes
mellitus (T2DM), costing the U.S. economy $412.9 billion in direct and indirect expenses. This
alarming trend underscores the urgent need for personalized therapies that enhance existing
treatments by tailoring drug selection to individual patient profiles. Precision based approaches
can optimize outcomes, reduce adverse effects, and improve long term disease management
across diverse populations. Our approach to addressing health disparities in diabetes focuses on
systemic barriers such as limited access to preventive care, delayed diagnoses, and insulin
unaffordability, factors that disproportionately impact economically vulnerable populations
regardless of race or background. To tackle these disparities, our project aims to build a
framework for evaluating T2DM medication efficacy using patient derived cellular models. By
generating personalized islet-like aggregates, we can predict drug responsiveness and tailor
treatment regimens to maximize benefit for each individual. This strategy not only advances
personalized diabetes care but also directly addresses unmet needs in disadvantaged
communities. Our goal is to deliver evidence based healthcare solutions that improve outcomes
and quality of life for all individuals living with diabetes. The project aims to reduce the economic
and health burdens of diabetes through tailored interventions and better access to personalized
care. Our research specifically targets the challenges faced by economically vulnerable
populations in the U.S., who experience higher mortality rates due to limited healthcare access
and preventive resources. This highlights a critical gap in our understanding of diabetes treatment
and risk factors in these groups. We propose a novel platform using patient specific induced
pluripotent stem cell (iPSC)-derived β-cells to evaluate diabetes medications and detect drug
resistance. This approach optimizes therapeutic outcomes and offers a scalable model for
reducing diabetes incidence and improving care in underserved communities. As the platform
matures, we plan to partner with hospitals and diabetes clinics to conduct personalized
assessments, enabling individualized treatment recommendations based on each patient’s
cellular response, starting with economically disadvantaged populations and scaling to broader
systems. Our Phase I project will validate the platform’s technical and commercial feasibility,
reduce development risks, and strategically position the company for growth in a competitive
market. Commercialization will begin with pilot studies in collaboration with clinics serving
vulnerable populations, supported by payer engagement, pharmacoeconomic analysis, and CLIA
compliant deployment to enable reimbursement and future FDA integration.
```



document fetched 2026-08-23 06:34